ECSP055998A - Composición farmacéutica que comprende ácido 5-metil-2-2'-(cloro-6'-fluoroanilino)fenilacético - Google Patents

Composición farmacéutica que comprende ácido 5-metil-2-2'-(cloro-6'-fluoroanilino)fenilacético

Info

Publication number
ECSP055998A
ECSP055998A EC2005005998A ECSP055998A ECSP055998A EC SP055998 A ECSP055998 A EC SP055998A EC 2005005998 A EC2005005998 A EC 2005005998A EC SP055998 A ECSP055998 A EC SP055998A EC SP055998 A ECSP055998 A EC SP055998A
Authority
EC
Ecuador
Prior art keywords
fluoroanilino
methyl
phenylacetic
chlorine
pharmaceutical composition
Prior art date
Application number
EC2005005998A
Other languages
English (en)
Inventor
Patrick Forenzo
Maha Y Khaled
Barbara Wang
Joseph Lawrence Zielinski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32990870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP055998(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP055998A publication Critical patent/ECSP055998A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan composiciones que comprenden suspensiones acuosas de ácido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacético adecuadas para administración oral. Se proporcionan métodos para hacer tales composiciones y métodos para su estabilización.
EC2005005998A 2003-03-12 2005-09-02 Composición farmacéutica que comprende ácido 5-metil-2-2'-(cloro-6'-fluoroanilino)fenilacético ECSP055998A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45414503P 2003-03-12 2003-03-12

Publications (1)

Publication Number Publication Date
ECSP055998A true ECSP055998A (es) 2006-01-27

Family

ID=32990870

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005998A ECSP055998A (es) 2003-03-12 2005-09-02 Composición farmacéutica que comprende ácido 5-metil-2-2'-(cloro-6'-fluoroanilino)fenilacético

Country Status (29)

Country Link
US (2) US20060094787A1 (es)
EP (1) EP1603550B1 (es)
JP (1) JP4580921B2 (es)
KR (1) KR20050109077A (es)
CN (1) CN100345536C (es)
AR (1) AR043536A1 (es)
AT (1) ATE418332T1 (es)
AU (1) AU2004218921B2 (es)
BR (1) BRPI0408270A (es)
CA (1) CA2518393A1 (es)
CL (1) CL2004000496A1 (es)
DE (1) DE602004018622D1 (es)
EC (1) ECSP055998A (es)
ES (1) ES2318277T3 (es)
HR (1) HRP20050787A2 (es)
IL (1) IL170518A (es)
IS (1) IS2658B (es)
MA (1) MA27670A1 (es)
MX (1) MXPA05009686A (es)
MY (1) MY139455A (es)
NO (1) NO20054662L (es)
NZ (1) NZ542218A (es)
PE (1) PE20041063A1 (es)
PT (1) PT1603550E (es)
RU (1) RU2363462C2 (es)
TN (1) TNSN05222A1 (es)
TW (1) TWI327913B (es)
WO (1) WO2004080451A1 (es)
ZA (1) ZA200506750B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037266A1 (en) * 2003-10-08 2005-04-28 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2’-chloro-6’-fluoroanilino)phenylacetic acid
KR100900915B1 (ko) * 2007-05-07 2009-06-05 이연제약주식회사 메게스트롤 아세테이트를 함유하는 현탁액 제제 및 이의제조방법
RU2488393C2 (ru) * 2007-11-12 2013-07-27 Новартис Аг Жидкие композиции, включающие валсартан
EP2926810A1 (en) * 2014-03-31 2015-10-07 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical formulations of loxoprofen
US11207307B2 (en) * 2016-06-16 2021-12-28 Azurity Pharmaceuticals, Inc. Composition and method for proton pump inhibitor suspension
US20190282500A1 (en) 2016-09-09 2019-09-19 Cutispharma, Inc. Suspensions and diluents for metronidazole and baclofen
US11433074B2 (en) 2017-06-22 2022-09-06 Triact Therapeutics, Inc. Methods of treating glioblastoma
EP3687501A4 (en) * 2017-09-29 2021-06-23 Triact Therapeutics, Inc. INIPARIB FORMULATIONS AND THEIR USES
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension
US10751333B1 (en) 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
US5840768A (en) * 1997-06-04 1998-11-24 Fmc Corporation MCC: alginate pharmaceutical suspensions
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US20020028794A1 (en) * 2000-07-21 2002-03-07 Brubaker Greg Allen Megestrol acetate suspension
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
EP1469846A2 (en) * 2002-01-07 2004-10-27 Pharmacia Corporation Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
AU2003223491A1 (en) * 2002-04-05 2003-10-27 Nitromed, Inc. Nitric oxide donors, compositions and methods of use

Also Published As

Publication number Publication date
JP4580921B2 (ja) 2010-11-17
IS2658B (is) 2010-08-15
TNSN05222A1 (en) 2007-06-11
EP1603550B1 (en) 2008-12-24
ZA200506750B (en) 2007-02-28
AU2004218921A1 (en) 2004-09-23
IL170518A (en) 2010-11-30
MA27670A1 (fr) 2005-12-01
JP2006519811A (ja) 2006-08-31
AU2004218921B2 (en) 2007-05-17
PT1603550E (pt) 2009-03-20
HK1086492A1 (en) 2006-09-22
CN100345536C (zh) 2007-10-31
NO20054662L (no) 2005-12-05
ATE418332T1 (de) 2009-01-15
NZ542218A (en) 2009-01-31
KR20050109077A (ko) 2005-11-17
MY139455A (en) 2009-10-30
NO20054662D0 (no) 2005-10-11
IS8049A (is) 2005-09-28
EP1603550A1 (en) 2005-12-14
PE20041063A1 (es) 2005-03-07
TWI327913B (en) 2010-08-01
CL2004000496A1 (es) 2005-01-14
ES2318277T3 (es) 2009-05-01
US20090048344A1 (en) 2009-02-19
US20060094787A1 (en) 2006-05-04
RU2005131310A (ru) 2006-05-10
HRP20050787A2 (en) 2006-12-31
CN1756541A (zh) 2006-04-05
RU2363462C2 (ru) 2009-08-10
DE602004018622D1 (de) 2009-02-05
WO2004080451A1 (en) 2004-09-23
MXPA05009686A (es) 2005-10-20
AR043536A1 (es) 2005-08-03
TW200505429A (en) 2005-02-16
BRPI0408270A (pt) 2006-03-07
CA2518393A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
UY27619A1 (es) Ésteres hidroxamato del ácido n-(4-fenil sustituido)- antranílico
GT200600258A (es) Derivados de n-(piridin-2-il)-sulfonamida
BRPI0407845A (pt) formulação intranasal de rotigotina
AP2001002217A0 (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids.
HN2002000319A (es) Benzamida, heteroarilamida y amidas inversas
EP2058317A4 (en) AMINOOPHOSPHORIC ACID DERTER DERIVATIVE AND THIS ACTIVE MODULATOR OF THE S1P RECEPTOR
EP2024272A4 (en) AMID DERIVATIVES AS ION CHANNEL NIGANDS, AND PHARMACEUTICAL COMPOSITIONS AND USER METHOD THEREFOR
UY27852A1 (es) Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
UY27516A1 (es) Bencimidazoles
BRPI0418330A (pt) composições sólidas de drogas de solubilidade baixa e poloxámeros
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
UA107560C2 (uk) Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
CY1118179T1 (el) Φαρμακευτικη συνθεση
UY27618A1 (es) Ésteres hidroxamato de ácido n-(4-fenil-sustituido)-antranílico
ECSP055998A (es) Composición farmacéutica que comprende ácido 5-metil-2-2'-(cloro-6'-fluoroanilino)fenilacético
MX2009012782A (es) Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados.
AR031761A1 (es) Kit de repinotano
SG152257A1 (en) Topical preparation containing ambroxol
BRPI0517413A (pt) composições farmacêuticas com gosto mascarado
BRPI0620229B8 (pt) formulações farmaceuticas e processos de produção da ditas formulações
BR0210327A (pt) Microcápsulas para proteção do hálito
GT200400068A (es) Derivados de 3-azabiciclo[3.2.1]octano
UY28422A1 (es) Sistemas emulsionantes que contienen derivados de azetidina
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
CL2008003919A1 (es) Compuestos derivados de y-lactona del acido 15a,16a-metilen-17-hidroxi-19-nor-17-pregna-4-en-3-ona-21-carboxilico; composicion farmaceutica que lo contiene y su uso para preparar medicamento para la contracepcion oral y para trastornos pre, peri y postmenopausicos.